North America was Ultragenyx Pharmaceutical’s largest region in fiscal 2025, bringing in $377.00M of $673.00M (56%).
| Geography | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| North America | $281.09M | $307.00M | $340.00M | $377.00M | ||||||
| Latin America | $44.71M | $77.00M | $131.00M | $170.00M | ||||||
| Europe, Middle East, & Africa | $36.37M | $48.00M | $80.00M | $108.00M | ||||||
| Europe | — | — | — | — | ||||||
| Asia-Pacific | $1.16M | $2.00M | $9.00M | $18.00M | ||||||
| All Other | — | — | — | — | ||||||
| United States Of America | — | — | — | — | ||||||
| Total | $363.33M | $434.00M | $560.00M | $673.00M |
Ultragenyx Pharmaceutical brought in $673.00M from its four regions in fiscal 2025, the year ended December 31, 2025. That was up 20.2% from $560.00M in fiscal 2024. North America was the largest at $377.00M (56.0%), ahead of Latin America at $170.00M (25.3%) and Europe, Middle East, & Africa at $108.00M (16.0%). The remaining region, Asia-Pacific, brought in $18.00M.
Compared with fiscal 2024, Asia-Pacific grew fastest, up 100.0% to $18.00M. Every region above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these regions grew from $363.33M to $673.00M, a compound annual growth rate of 22.8%. North America's share of the total fell from 77.4% to 56.0%.
Product Sales was Ultragenyx Pharmaceutical’s largest product and service line in fiscal 2025, bringing in $369.00M of $673.00M (55%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Royalty | — | $183.00M | $275.00M | $304.00M | ||||||
| Non-Cash Collaboration Royalty Revenue | $21.69M | — | — | — | ||||||
| Collaboration & License | $222.71M | $71.00M | — | — | ||||||
| Product Sales | $118.93M | $180.00M | $285.00M | $369.00M | ||||||
| Collaboration & Royalty | — | — | — | — | ||||||
| Total | $363.33M | $434.00M | $560.00M | $673.00M |
Ultragenyx Pharmaceutical brought in $673.00M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 20.2% from $560.00M in fiscal 2024. Product Sales was the largest at $369.00M (54.8%), ahead of Royalty at $304.00M (45.2%).
Compared with fiscal 2024, Product Sales grew 29.5% to $369.00M and Royalty grew 10.5% to $304.00M.
Ultragenyx Pharmaceutical began breaking out Royalty in fiscal 2023, when it brought in $183.00M. Ultragenyx Pharmaceutical stopped reporting Collaboration & License ($71.00M in fiscal 2023) and Non-Cash Collaboration Royalty Revenue ($21.69M in fiscal 2022) as separate lines.
Crysvita was Ultragenyx Pharmaceutical’s largest revenue line in fiscal 2025, bringing in $481.00M of $673.00M (71%).
| Collaborative Arrangement and Arrangement Other than Collaborative | FY 2016 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Crysvita | $328.00M | $410.00M | $481.00M | |
| Dojolvi | $71.00M | $88.00M | $96.00M | |
| Evkeeza | $4.00M | $32.00M | $59.00M | |
| Mepsevii | $30.00M | $30.00M | $37.00M | |
| Total | $433.00M | $560.00M | $673.00M |
Ultragenyx Pharmaceutical brought in $673.00M from its four revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 20.2% from $560.00M in fiscal 2024. Crysvita was the largest at $481.00M (71.5%), ahead of Dojolvi at $96.00M (14.3%) and Evkeeza at $59.00M (8.8%). The remaining revenue line, Mepsevii, brought in $37.00M.
Compared with fiscal 2024, Evkeeza grew fastest, up 84.4% to $59.00M. Every revenue line above 2% of revenue grew. From fiscal 2023 to 2025, combined revenue from these revenue lines grew from $433.00M to $673.00M, a compound annual growth rate of 24.7%. Crysvita's share of the total fell from 75.8% to 71.5%.
Ultragenyx Pharmaceutical (RARE) reports its revenue by geography, by product and service and by collaborative arrangement and arrangement other than collaborative. In fiscal 2025, North America was its largest region, bringing in $377.00M (56.0% of the total), followed by Latin America at $170.00M (25.3%).
North America was Ultragenyx Pharmaceutical's largest region in fiscal 2025, bringing in $377.00M, or 56.0% of the $673.00M total across its four regions.
Product Sales was Ultragenyx Pharmaceutical's largest product and service line in fiscal 2025, bringing in $369.00M, or 54.8% of the $673.00M total across its two product and service lines.
Crysvita was Ultragenyx Pharmaceutical's largest revenue line in fiscal 2025, bringing in $481.00M, or 71.5% of the $673.00M total across its four revenue lines.
Among Ultragenyx Pharmaceutical's regions that make up at least 2% of revenue, Asia-Pacific grew fastest in fiscal 2025, up 100.0% from $9.00M to $18.00M.
Every figure comes from Ultragenyx Pharmaceutical's annual financial filings, as reported. Each line keeps the name Ultragenyx Pharmaceutical gives it, and years follow its fiscal calendar.
Ultragenyx Pharmaceutical's revenue by geography goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.